Valeant Pharmaceuticals, Uni-Pixel, Bristol-Myers Squibb, Sanofi and Pfizer highlighted as Zacks Bull and Bear of the Day

 Valeant Pharmaceuticals, Uni-Pixel, Bristol-Myers Squibb, Sanofi and Pfizer
                highlighted as Zacks Bull and Bear of the Day

PR Newswire

CHICAGO, Oct. 14, 2013

CHICAGO, Oct. 14, 2013 /PRNewswire/ --Zacks Equity Research highlights
Valeant Pharmaceuticals (NYSE:VRX-Free Report) as the Bull of the Day and
Uni-Pixel (Nasdaq:UNXL-Free Report) as the Bear of the Day. In addition, Zacks
Equity Research provides analysis on the Bristol-Myers Squibb Company
(NYSE:BMY-Free Report), Sanofi (NYSE:SNY-Free Report) and Pfizer Inc.
(NYSE:PFE-Free Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Here is a synopsis of all five stocks:

Bull of the Day:

Looking for a healthcare play with strong consumer products growth and an
expanding pharmaceutical pipeline? Then set your sights on Canada's Valeant
Pharmaceuticals (NYSE:VRX-Free Report), whose recently completed acquisition
of Bausch & Lomb makes it the biggest player in ophthalmology and general
eyecare products.

Valeant is a specialty pharmaceutical company with many hundreds of products
across dermatology, dentistry, neurology, and ophthalmology. Its early and
late-stage drug candidates have unique formulations and mechanisms of action
including retigabine for the treatment of epilepsy and pain, taribavirin of
the treatment of chronic hepatitis C, and several dermatology candidates for
the treatment of rosacea, acne, and dermatological fungus.

The company has been primarily built through a series of mergers and
acquisitions over the years. It operates in two primary geographical segments,
Developed Markets and Emerging Markets. Developed Markets includes U.S.
pharma/OTC in dermatology, aesthetics, dentistry, podiatry, ophthalmology,
neurology/other, and Canada/Australia/NZ. Emerging Markets includes branded
generics/OTC in Central/Eastern Europe, Latin America, SE Asia/Africa.

This growth strategy is producing over 50% sales growth and 40% EPS growth,
while trading under 13X next year's $8.66 consensus. And that's why the stock
keeps steadily climbing since May. It's that kind of stable, global growth
that some investors can't get enough of.

Bear of the Day:

Uni-Pixel (Nasdaq:UNXL-Free Report) designs and develops functional electronic
conductive films and durable wear resistance films used in sensors and display
applications for consumer and industrial products. The $200 million company
had virtually no revenues in 2012 and is projected to have only $21 million
this year.

Uni-Pixel's patented technology, the Time Multiplexed Optical Shutter (TMOS),
can be used in mobile phones, digital cameras, notebook computers,
televisions, as well as display and interactive technologies in the energy,
transportation and entertainment industries.

The future of touch, sensor, and gesture technologies looks bright, with
Oppenheimer projecting the consumer gesture control market to be the fastest
growing segment as it expands fivefold from $850 million in 2013 to over $4
billion by 2017. That's a compound annual growth rate of 50%!

But the recent backslide in sales at UNXL has forced analysts to cut 2013
earnings estimates in the past two months from an expected gain of $0.46 to a
loss of 5 cents. And just last week, that profit outlook got cut in half again
with the consensus now at a loss of 10 cents for the year.

Additional content:

Bristol-Myers Upgraded from Underperform

We are reverting to a Neutral recommendation on Bristol-Myers Squibb Company
(NYSE:BMY-Free Report) from Underperform as we believe that the current price
reflects all the negative news. Consequently, there is limited scope for stock
price appreciation at Bristol-Myers. The stock carries a Zacks Rank #3 (Hold)
in the short run.

Why Back to Neutral?

Bristol-Myers reported earnings (excluding special items) of 44 cents per
share in the second quarter of 2013, down 9% from the year-ago figure. The
decline was due to reduced sales of Plavix and Avapro. Both drugs,
co-developed with Sanofi (NYSE:SNY-Free Report), went off patent in the U.S.
last year.

The genericization of Plavix and Avapro in the U.S. has resulted in a
significant loss of revenues. The modest revenues reported by the company in
the second quarter of 2013 were primarily due to lower sales of both drugs.

Avapro/Avalide recorded a 52% decline in global net sales to $56 million in
the second quarter of 2013. Global net sales of Plavix plummeted 94% to $44
million in the second quarter of 2013. U.S. sales of the drug plunged 97% to
$18 million. We believe that Bristol-Myers has entered a challenging period
following Plavix's genericization.

Following the lackluster performance, the company trimmed its 2013 guidance.
Bristol-Myers now expects adjusted earnings for 2013 in the range of
$1.70-$1.78 (old guidance: $1.78–$1.88). The company slashed its outlook
reflecting negative currency movement and the recall of Fervex, a local OTC
product in France and other international markets. Bristol-Myers also cut its
revenue guidance. Moreover, anti-clotting drug, Eliquis, co-developed with
Pfizer Inc. (NYSE:PFE-Free Report) also performed disappointingly in the
second quarter of 2013.

We believe the current price incorporates all the negative news and are
reverting to a Neutral recommendation on the stock.

Get today's Zacks #1 Stock of the Day with your free subscription to Profit
from the Pros newsletter:

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Click here to subscribe to this
free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Pros.

Get the full Report on VRX - FREE

Get the full Report on UNXL - FREE

Get the full Report on BMY - FREE

Get the full Report on SNY - FREE

Get the full Report on PFE - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such
affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Zacks.com provides investment resources and informs you of these resources,
which you may choose to use in making your own investment decisions. Zacks is
providing information on this resource to you subject to the Zacks "Terms and
Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com